Aspira Womens Health is engaged in the discovery, development and commercialization of diagnostic and bio-analytical solutions. Co.'s products and related services include: OVA1, a blood test designed to, in addition to a physician's clinical assessment of a woman with a pelvic mass, identify women who are at high risk of having a malignant ovarian tumor prior to planned surgery; Overa, a biomarker panel; OVA1PLUS, a service offering combining its OVA1 and Overa products; and ASPiRA GenetiX, a genetic test for women's health diseases, which is focused on detecting hereditary breast and ovarian cancer syndrome; and Carrier screening, genetic screening for carriers of disease. The AWH stock yearly return is shown above.
The yearly return on the AWH stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2014 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AWH annual return calculation with any dividends reinvested as applicable (on ex-dates).
|